Citius Pharmaceuticals, Inc.
CTXR
$0.58
-$0.02-3.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.97% | 302.70% | 26.39% | -16.47% | -8.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.92% | 185.43% | 23.41% | -23.65% | -17.36% |
| Operating Income | -13.93% | -170.63% | 15.88% | 23.65% | 17.36% |
| Income Before Tax | -34.53% | -151.98% | 8.86% | 22.44% | 14.28% |
| Income Tax Expenses | -140.61% | -187.51% | 0.00% | 83.47% | 83.47% |
| Earnings from Continuing Operations | -29.50% | -144.19% | 8.63% | 21.07% | 12.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 638.26% | 1,056.07% | 128.67% | 173.31% | -- |
| Net Income | -0.83% | -94.49% | 15.84% | 26.24% | 16.87% |
| EBIT | -13.93% | -170.63% | 15.88% | 23.65% | 17.36% |
| EBITDA | -- | -165.54% | 21.59% | 23.65% | 17.36% |
| EPS Basic | 57.59% | 25.41% | 70.67% | 70.93% | 49.02% |
| Normalized Basic EPS | 72.49% | 27.55% | 74.68% | 70.99% | 49.86% |
| EPS Diluted | 57.59% | 25.41% | 70.67% | 70.93% | 49.02% |
| Normalized Diluted EPS | 72.49% | 27.55% | 74.68% | 70.99% | 49.86% |
| Average Basic Shares Outstanding | 137.76% | 160.76% | 186.89% | 137.75% | 58.27% |
| Average Diluted Shares Outstanding | 137.76% | 160.76% | 186.89% | 137.75% | 58.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |